Compare prices and buy Cerebrolysin from 7 research peptide vendors - also called suppliers or sources. Updated daily.
A porcine-brain-derived hydrolysate (CAS 12656-61-0) consisting of a mixture of peptides and free amino acids, made by the Austrian company EVER Pharma and described in the literature as a neurotrophic agent. It is a prescription medicine outside the United States, used mainly in stroke and traumatic brain injury, and it is not FDA-approved.
For research purposes only. Not medical advice.
Cerebrolysin is a prescription medicine made from pig brain by the Austrian company EVER Pharma, and it is not a single peptide. The summary of product characteristics (SmPC) for its Polish authorization states that each milliliter of solution contains 215.2 mg of a mixture of peptides obtained from pig brain. The 2023 Cochrane review of its use in stroke describes it as a mixture of low-molecular-weight peptides and amino acids.
Because it is a mixture, it has no single sequence, molecular formula or molecular weight. PubChem holds substance records deposited under the name but no compound record for Cerebrolysin or for CAS 12656-61-0, and the SmPC states that no ATC code has yet been assigned to it. It is catalogued under Nootropic and Neurological because research vendors sell it alongside the nootropic peptides there, a commercial overlap rather than a chemical kinship.
The SmPC attributes its activity to the peptide fraction as a whole. It states that the fraction stimulates cell differentiation, supports neuronal function and activates protective and repair processes. In animal studies, the label says, Cerebrolysin acted on neuronal and synaptic plasticity and improved learning, and in models of cerebral ischemia it reduced the area of ischemic necrosis and inhibited edema formation.
Its pharmacokinetics are described only indirectly. The SmPC states that the fraction consists of short, naturally occurring peptides similar or identical to ones produced in the human body, that direct measurement of its pharmacokinetic properties was unsuccessful, and that its neurotrophic activity is detectable in blood plasma for up to 24 hours after a single administration.
The CASTA trial, funded by EVER Neuro Pharma and published in Stroke in 2012, randomized 1,070 patients with acute ischemic hemispheric stroke at sites in China, Hong Kong, South Korea and Myanmar to Cerebrolysin or placebo within 12 hours of symptom onset, both alongside aspirin, and followed them for 90 days. Its primary endpoint, a combined test of the modified Rankin Scale, Barthel Index and NIH Stroke Scale, showed no significant difference between the groups in the trial's confirmatory analysis. A post hoc analysis found a trend favoring Cerebrolysin among patients with an NIH Stroke Scale score above 12, which the authors said a further trial should confirm.
The Cochrane review of Cerebrolysin for acute ischemic stroke, updated in 2023 by Ziganshina and colleagues, pooled randomized trials that started treatment within 48 hours of onset and compared it with placebo or no treatment. Across six trials and 1,689 participants, including one trial of Cortexin, a Russian brain-extract peptide mixture, it found that treatment probably makes little to no difference to all-cause death (risk ratio 0.96, 95% CI 0.65 to 1.41, moderate certainty). Across three Cerebrolysin trials and 1,335 participants it found more people with non-fatal serious adverse events in the treated groups (risk ratio 2.39, 95% CI 1.10 to 5.23, moderate certainty). The review notes that the manufacturer supported three of the multicenter trials. It excluded the CARS trial of recovery after stroke as addressing a different research question, and a CARS investigator disputed that selection in feedback on the review's 2020 version.
Cerebrolysin is authorized as a medicine outside the United States and holds no US approval. Poland's register of medicinal products lists it as a solution for injection and infusion held by EVER Neuro Pharma GmbH under national authorization 08135, with unlimited validity, and its SmPC dates the first Polish authorization to June 12, 2000. The label's indications are supportive treatment in Alzheimer-type and vascular dementia, deficits after stroke, and craniocerebral trauma. The Cochrane review describes wide use in stroke in Russia, Eastern Europe, China and other Asian and post-Soviet countries.
Searches run on October 21, 2026 found it on none of these FDA sources.
No. Cerebrolysin is a preparation made from pig brain. The summary of product characteristics for EVER Pharma's medicine states that each milliliter of solution contains 215.2 mg of a mixture of peptides obtained from pig brain, and the 2023 Cochrane review describes it as a mixture of low-molecular-weight peptides and amino acids. Because it is a mixture, it has no single amino acid sequence, molecular formula or molecular weight, and PubChem holds no compound record for it.
No. As of October 21, 2026 drugsfda returns no application for Cerebrolysin, and it is named neither on FDA's Category 2 page of bulk drug substances that may present significant safety risks nor on the 503A nominations list updated May 14, 2026 or the 503B nominations list updated March 21, 2025. It is authorized as a medicine outside the United States. Poland's register of medicinal products lists it as a solution for injection and infusion held by EVER Neuro Pharma, first authorized there in 2000.
CASTA, funded by EVER Neuro Pharma and published in Stroke in 2012, randomized 1,070 patients with acute ischemic stroke in Asia to Cerebrolysin or placebo, both alongside aspirin, within 12 hours of symptom onset. Its primary endpoint, a combined test of disability, daily-living and stroke-severity scales at 90 days, showed no significant difference between the groups. A post hoc analysis found a trend favoring Cerebrolysin in the most severely affected patients, which the authors said a further trial should confirm.
The 2023 update of the Cochrane review of Cerebrolysin for acute ischemic stroke pooled randomized trials against placebo or no treatment. It found, with moderate certainty, that Cerebrolysin or the similar brain-extract mixture Cortexin probably makes little to no difference to all-cause death, a risk ratio of 0.96 across six trials and 1,689 participants. It also found, with moderate certainty, more people with non-fatal serious adverse events on Cerebrolysin, a risk ratio of 2.39 across three trials and 1,335 participants.
The Polish label for EVER Pharma's Cerebrolysin describes a clear amber solution for injection and infusion supplied in glass ampoules, with the strength stated per milliliter. The research listings PeptideScouter indexes are vials labeled by milligram content, and the product pages read for this entry describe them as lyophilized powder.
Cerebrolysin is sold by 7 research peptide vendors indexed on PeptideScouter, with 10 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
All 7 indexed research peptide vendors currently have Cerebrolysin in stock. Stock state is refreshed daily from each vendor's catalog.
Disguised Alpha currently lists Cerebrolysin at $0.33/mg, the lowest listed price across 7 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $0.29/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 7 vendors listing Cerebrolysin publish a PeptideScouter code, worth 10% to 15% off. Applied, the lowest effective price falls from $0.33/mg listed to $0.29/mg at Disguised Alpha. Each vendor's code is shown beside its price in the table above.
Cerebrolysin ranges from $0.33/mg to $1.17/mg across 10 listings from 7 research peptide vendors, normalized to USD per milligram and refreshed daily.
7 research peptide vendors currently list Cerebrolysin on PeptideScouter. We track 10 listings across size and kit variants.
Cerebrolysin's CAS Registry Number is 12656-61-0. It is also sold as Cerebroprotein Hydrolysate, Cerebrolysin (Cerebroprotein Hydrolysate).
